Identification of MFGE8 in mesenchymal stem cell secretome as an anti-fibrotic factor in liver fibrosis

Yu Jin Jang, Su Yeon An, Jong-Hoon Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The beneficial paracrine roles of mesenchymal stem cells (MSCs) in tissue repair have potential in therapeutic strategies against various diseases. However, the key therapeutic factors secreted from MSCs and their exact molecular mechanisms of action remain unclear. In this study, the cell-free secretome of umbilical cord-derived MSCs showed significant anti-fibrotic activity in the mouse models of liver fibrosis. The involved action mechanism was the regulation of hepatic stellate cell activation by direct inhibition of the TGFβ/Smad-signaling. Antagonizing the milk fat globule-EGF factor 8 (MFGE8) activity blocked the anti-fibrotic effects of the MSC secretome in vitro and in vivo. Moreover, MFGE8 was secreted by MSCs from the umbilical cord as well as other tissues, including teeth and bone marrow. Administration of recombinant MFGE8 protein alone had a significant anti-fibrotic effect in two different models of liver fibrosis. Additionally, MFGE8 downregulated TGFβ type I receptor expression by binding to αvβ3 integrin on HSCs. These findings revealed the potential role of MFGE8 in modulating TGFβ-signaling. Thus, MFGE8 could serve as a novel therapeutic agent for liver fibrosis.

Original languageEnglish
Pages (from-to)58-59
Number of pages2
JournalBMB Reports
Volume50
Issue number2
DOIs
Publication statusPublished - 2017

Fingerprint

Stem cells
Mesenchymal Stromal Cells
Epidermal Growth Factor
Liver Cirrhosis
Liver
Umbilical Cord
Tissue
Hepatic Stellate Cells
Integrins
milk fat globule
Tooth
Bone
Repair
Therapeutics
Down-Regulation
Bone Marrow
Chemical activation
Proteins

Keywords

  • Liver fibrosis
  • MFGE8
  • MSC
  • Secretome

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

Identification of MFGE8 in mesenchymal stem cell secretome as an anti-fibrotic factor in liver fibrosis. / Jang, Yu Jin; An, Su Yeon; Kim, Jong-Hoon.

In: BMB Reports, Vol. 50, No. 2, 2017, p. 58-59.

Research output: Contribution to journalArticle

@article{498e13e5e75a47c7b1b496e5e3a4a98a,
title = "Identification of MFGE8 in mesenchymal stem cell secretome as an anti-fibrotic factor in liver fibrosis",
abstract = "The beneficial paracrine roles of mesenchymal stem cells (MSCs) in tissue repair have potential in therapeutic strategies against various diseases. However, the key therapeutic factors secreted from MSCs and their exact molecular mechanisms of action remain unclear. In this study, the cell-free secretome of umbilical cord-derived MSCs showed significant anti-fibrotic activity in the mouse models of liver fibrosis. The involved action mechanism was the regulation of hepatic stellate cell activation by direct inhibition of the TGFβ/Smad-signaling. Antagonizing the milk fat globule-EGF factor 8 (MFGE8) activity blocked the anti-fibrotic effects of the MSC secretome in vitro and in vivo. Moreover, MFGE8 was secreted by MSCs from the umbilical cord as well as other tissues, including teeth and bone marrow. Administration of recombinant MFGE8 protein alone had a significant anti-fibrotic effect in two different models of liver fibrosis. Additionally, MFGE8 downregulated TGFβ type I receptor expression by binding to αvβ3 integrin on HSCs. These findings revealed the potential role of MFGE8 in modulating TGFβ-signaling. Thus, MFGE8 could serve as a novel therapeutic agent for liver fibrosis.",
keywords = "Liver fibrosis, MFGE8, MSC, Secretome",
author = "Jang, {Yu Jin} and An, {Su Yeon} and Jong-Hoon Kim",
year = "2017",
doi = "10.5483/BMBRep.2017.50.2.012",
language = "English",
volume = "50",
pages = "58--59",
journal = "BMB Reports",
issn = "1976-6696",
publisher = "The Biochemical Society of the Republic of Korea",
number = "2",

}

TY - JOUR

T1 - Identification of MFGE8 in mesenchymal stem cell secretome as an anti-fibrotic factor in liver fibrosis

AU - Jang, Yu Jin

AU - An, Su Yeon

AU - Kim, Jong-Hoon

PY - 2017

Y1 - 2017

N2 - The beneficial paracrine roles of mesenchymal stem cells (MSCs) in tissue repair have potential in therapeutic strategies against various diseases. However, the key therapeutic factors secreted from MSCs and their exact molecular mechanisms of action remain unclear. In this study, the cell-free secretome of umbilical cord-derived MSCs showed significant anti-fibrotic activity in the mouse models of liver fibrosis. The involved action mechanism was the regulation of hepatic stellate cell activation by direct inhibition of the TGFβ/Smad-signaling. Antagonizing the milk fat globule-EGF factor 8 (MFGE8) activity blocked the anti-fibrotic effects of the MSC secretome in vitro and in vivo. Moreover, MFGE8 was secreted by MSCs from the umbilical cord as well as other tissues, including teeth and bone marrow. Administration of recombinant MFGE8 protein alone had a significant anti-fibrotic effect in two different models of liver fibrosis. Additionally, MFGE8 downregulated TGFβ type I receptor expression by binding to αvβ3 integrin on HSCs. These findings revealed the potential role of MFGE8 in modulating TGFβ-signaling. Thus, MFGE8 could serve as a novel therapeutic agent for liver fibrosis.

AB - The beneficial paracrine roles of mesenchymal stem cells (MSCs) in tissue repair have potential in therapeutic strategies against various diseases. However, the key therapeutic factors secreted from MSCs and their exact molecular mechanisms of action remain unclear. In this study, the cell-free secretome of umbilical cord-derived MSCs showed significant anti-fibrotic activity in the mouse models of liver fibrosis. The involved action mechanism was the regulation of hepatic stellate cell activation by direct inhibition of the TGFβ/Smad-signaling. Antagonizing the milk fat globule-EGF factor 8 (MFGE8) activity blocked the anti-fibrotic effects of the MSC secretome in vitro and in vivo. Moreover, MFGE8 was secreted by MSCs from the umbilical cord as well as other tissues, including teeth and bone marrow. Administration of recombinant MFGE8 protein alone had a significant anti-fibrotic effect in two different models of liver fibrosis. Additionally, MFGE8 downregulated TGFβ type I receptor expression by binding to αvβ3 integrin on HSCs. These findings revealed the potential role of MFGE8 in modulating TGFβ-signaling. Thus, MFGE8 could serve as a novel therapeutic agent for liver fibrosis.

KW - Liver fibrosis

KW - MFGE8

KW - MSC

KW - Secretome

UR - http://www.scopus.com/inward/record.url?scp=85014128325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014128325&partnerID=8YFLogxK

U2 - 10.5483/BMBRep.2017.50.2.012

DO - 10.5483/BMBRep.2017.50.2.012

M3 - Article

C2 - 28115038

AN - SCOPUS:85014128325

VL - 50

SP - 58

EP - 59

JO - BMB Reports

JF - BMB Reports

SN - 1976-6696

IS - 2

ER -